Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.
Pfizer has officially declared its £69 billion bid to acquire AstraZeneca dead - but hasn't ruled out another attempt in a few months' time. The US company has been in open pursuit of AstraZeneca ...
A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
The company is already working with multiple large hospitals in the U.S. and Israel, as well as drug companies, including AstraZeneca and Pfizer. Promise Bio is now emerging from stealth with a ...
The Pfizer and AstraZeneca coronavirus vaccines are highly effective against the variant identified in India after two doses, a study has found. Two jabs of either vaccine give a similar level of ...
Two vaccines were studied: those made by Pfizer and AstraZeneca. So, is mix and match an option? The trial’s results are preliminary, having yet to be reviewed by other scientists, but the answer ...
The UK medicines regulator has approved the use of Pfizer and AstraZeneca as Covid booster vaccines, paving the way for a rollout ahead of the winter. But the Joint Committee on Vaccination and ...
These goals address a wide range of global challenges, including climate change, the biodiversity crisis, and pressing health ...
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Dr. Mackay is a highly accomplished R&D executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. SpringWorks uses ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback